

CHANGES IN HEALTHCARE RESOURCE USE (HCRU) AND COSTS IN COMMERCIALLY INSURED INSOMNIA PATIENTS INITIATING SUVOREXANT

Hrishikesh P. Kale; Zaina P. Qureshi; Ruchit Shah; Rezaul Khandker; Marc Botteman; Weilin Meng; Ruth Benca

DOI: <https://doi.org/10.1007/s12325-021-01891-8>

SUVOREXANT WAS ASSOCIATED WITH A DECREASE IN ALL-CAUSE HCRU AND COSTS IN A 1-YEAR REAL-WORLD STUDY

Burden of Insomnia Disorder in the US




Prevalence




10-25%
but may vary from 5% to 50%

PREVALENT COHORT



INCIDENT COHORT




MENTAL HEALTH COMORBIDITIES

Among a subgroup of patients with mental health disorders on suvorexant, cost reductions were **1.5-3 times greater** than those for the overall cohort.


ANALYSIS

Interrupted Time Series (ITS)
Level and slope changes



CHANGES IN TOTAL HEALTHCARE COSTS BEFORE AND AFTER SUVOREXANT ADMINISTRATION*

Prevalent Cohort Data Analysis



Total healthcare costs change before suvorexant initiation:

Prevalent cohort: \$52.51 **increase** per month
Incident cohort: \$74.93 **increase** per month

Total healthcare costs change after suvorexant initiation:

Prevalent cohort: \$72.66 **decrease** per month
Incident cohort: \$112.07 **decrease** per month

*Please refer to the journal article for a full analysis of prevalent and incident cohort data.

PEER-REVIEWED
INFOGRAPHIC

Adis

OPEN
ACCESS

This graphical abstract represents a summary of the article. For a full list of declarations, including funding and author disclosure statements, please see the full text online. ©The authors, CC-BY-NC 2021.